Nachrichten zur Hims & Hers Health Inc. Aktie

HIMS Breakout Signals Structural Business Transformation

Hims & Hers stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a…

Hims & Hers Health (HIMS) Secures $400 Million Financing, Is The Upside Already Priced In?

Hims & Hers Health (HIMS) is back in focus after securing a $400 million financing arrangement with JPMorgan Chase Bank.…

Price to book forward of Hims & Hers Health, Inc. Registered Shs A Cert Deposito Arg Repr 0.25 Shs – BCBA:HIMS.CI

Price to book forward, quarterly and annual stats of Hims & Hers Health, Inc. Registered Shs A Cert Deposito Arg…

Hims & Hers Establishes New $400 Million Receivables Facility

Hims & Hers Health ( ($HIMS) ) has provided an announcement. On July 1, 2026, XeCare LLC and Apostrophe Pharmacy…

Hims & Hers Launches $400 Million Receivables Facility, Amends Revolver to Support Program

Hims & Hers Health established a $400 million Master Receivables Purchase Agreement with JPMorgan Chase Bank, enabling the sale of…

Hims & Hers sets $400M receivables facility

Hims & Hers set a $400M receivables purchase facility with JPMorgan and amended its revolving credit agreement to permit the…

HIMS Stock Surges as Canaccord Genuity Raises Price Target

On July 01, 2026, Hims & Hers Health Inc (HIMS) experienced a significant stock price increase following a price target…

Hims & Hers Stock Surges as Analysts Lift Price Targets - Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health Inc (NYSE:HIMS) shares are rising on Wenesday after B of A Securities and Canaccord Genuity raised…

Hims & Hers stock jumps as Canaccord lifts target ahead of FDA review

Hims & Hers Health shares (HIMS) surged 9% on Wednesday after Canaccord Genuity raised its price target on the telehealth…

Hims & Hers Health (NYSE:HIMS) run trims Canaccord upside after GLP-1 reset

Hims & Hers Health (NYSE:HIMS) run trims Canaccord upside after GLP-1 reset - TechStock²…

BofA raises Hims and Hers stock price target on FDA peptide review

BofA raises Hims and Hers stock price target on FDA peptide review…

Four stock-moving events to watch as FDA revives AdComs

Hims & Hers Health (HIMS) stock, Replimune (REPL) stock, and Capricor (CAPR) stock are in focus as the FDA…

Canaccord Genuity raised its price target on Hims & Hers to $40, citing stronger sales momentum in weight-loss drugs and peptide opportunities.

The telehealth companys strong partnership with Novo Nordisk and accelerating sales momentum drove the analyst upgrade as Medicare expands GLP-1…

HIMS Maintained by Canaccord Genuity -- Price Target Raised to $40

On October 03, 2023, Canaccord Genuity maintained a Buy rating for Hims & Hers Health (HIMS). Analyst Maria Ripps has…

Why is Hims & Hers Health stock rallying today?

Why is Hims & Hers Health stock rallying today?…

Hims & Hers stock rises after Canaccord price target hike

Hims & Hers stock rises after Canaccord price target hike…

HIMS Maintains by B of A Securities -- Price Target Raised to $36

On October 03, 2023, the latest analyst rating for Hims & Hers Health Inc (HIMS) has been released by B…

Hims & Hers Health, Inc. Stock 12?Month Price Target Raised to $29.27, Implies 16% Downside

Explore more price target data and ratings for Hims & Hers Health, Inc. on the Forecasts tab, and track all…

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine…

Canaccord raises Hims and Hers stock price target on weight loss drugs

Canaccord raises Hims and Hers stock price target on weight loss drugs…

Canaccord raises Hims and Hers stock price target on weight loss drugs

Canaccord raises Hims and Hers stock price target on weight loss drugs…

Hims & Hers Recruits Longevity Specialist Anant Vinjamoori as Hims Chief Medical Officer

Hims & Hers has appointed preventive health and longevity specialist Anant Vinjamoori as the Chief Medical Officer for the Hims…

Hims & Hers stock jumps as Canaccord lifts target ahead of FDA review

Hims & Hers stock jumps as Canaccord lifts target ahead of FDA review…

Hims & Hers stock jumps as Canaccord lifts target price ahead of FDA review

Hims & Hers stock jumps as Canaccord lifts target price ahead of FDA review…

Hims & Hers price target raised to $36 from $25 at BofA

BofA analyst Allen Lutz raised the firm’s price target on Hims Hers to $36 from $25 and keeps a…

Hims & Hers Health Aktie: FDA-Risiken treffen auf neue Wachstumschancen - Peptidfantasie bleibt intakt

Vancouver (www.aktiencheck.de) - Hims & Hers Health-Aktienanalyse von Canaccord Genuity:Die Analysten von Canaccord Genuity stufen die Aktie von Hims &…

Hims & Hers Health Inc (HIMS) Shares Surge 3.8% -- What GF Score of 81 Tells Investors

On June 30, 2026, Hims & Hers Health Inc (HIMS) shares rose 3.8% to a current price of $34.67. The…

What triggered Hims & Hers Health shares latest price pullback

Hims & Hers Health slides 2.31% today to $32.62 as selling pressure reverses early momentum and caps the stock near…

Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $33.39, indicating a -1.62% shift from…

Will Novo Nordisk’s GLP-1 Telehealth Tie-Up Change Hims & Hers Healths (HIMS) Cash-Pay Narrative

Earlier this year, Novo Nordisk announced a partnership with Hims & Hers Health to offer branded GLP-1 weight-loss drugs through…

Trading the Move, Not the Narrative: (HIMS) Edition

Price-action only: Hims & Hers Health Inc. Class A (HIMS) movements set the tone for institutional models. Trading the Move,…

Hims & Hers Soars After Novo Nordisk Weight-Loss Nod

Hims & Hers Health ( ($HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual…

Hims & Hers: Can Fundamentals Really Support This Rebound Rally? (Downgrade)

Hims & Hers has rebounded nearly 40% since my last buy rating at $22, despite recent fundamental setbacks. Learn more…

Hims & Hers poised to benefit as insurers pull back on weight-loss drug coverage

Analysts expect the telehealth company to attract more direct-pay customers as employers reconsider coverage of costly GLP-1 drugs.…

Telehealth Revolution: Hims & Hers Navigates Weight-Loss Drug Market Amid Employer Cutbacks

Hims & Hers Health could see a growth surge as employers drop coverage for weight-loss drugs due to soaring costs.…

Hims & Hers shares dip amid rising selling pressure

Hims & Hers Health slips 2.35% today to $31.93 as technical selling emerges; momentum mixed near key averages and support.…

Hims & Hers Stock Tumbles As Regulatory Jitters Spike

Hims & Hers Health ( ($HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual…

$30.79 support helps Hims & Hers Health stock trade flat despite recent pullback

Hims & Hers Health trades at $32.7 today, slipping 0.79%. Check key support and resistance levels in the latest technical…

Barclays Raises Price Target On Hims & Hers Health (NYSE: HIMS) As Weight Loss Business Drives Momentum

Barclays has maintained its Overweight rating on Hims & Hers Health, Inc. (NYSE: HIMS) while raising its price target to…

Is Hims & Hers Health, Inc. (HIMS) a Top Weight Loss Stock After Barclays’ Target Increase?

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Hims & Hers…

Hims & Hers Health (HIMS) Expands GLP 1 Reach, Is The Upside Already Priced In?

Hims & Hers Health (HIMS) is back in focus as investors weigh its expanding GLP-1 weight-loss offering, its new partnership…

Top Hims & Hers Executive Makes Major Move With Company Stock

New insider activity at Hims & Hers Health ( ($HIMS) ) has taken place on June 23, 2026. Hims &…

Hims & Hers CFO Oluyemi Okupe sells $619,216 in shares

Hims & Hers CFO Oluyemi Okupe sells $619,216 in shares…

Hims & Hers CMO Patrick Carroll sells $830,410 in stock

Hims & Hers CMO Patrick Carroll sells $830,410 in stock…

Hims & Hers CMO sells 23,726 shares at $35

Hims & Hers Health Chief Medical Officer Patrick Harrison sold 23,726 shares at $35.00 each and now directly holds 181,861…

[Form 4] Hims & Hers Health, Inc. Insider Trading Activity

Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported an exercise of stock options and a sale of…

Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $32.96, moving 1.73% from the previous trading…

Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $32.96, moving 1.73% from the previous trading…

Hims & Hers Health (NYSE: HIMS) Bets On GLP-1 Growth With Novo Nordisk Partnership And Eucalyptus Acquisition

Hims & Hers Health (NYSE: HIMS) is deepening its push into prescription weight management by adding new GLP-1 treatment options…

Hims & Hers Health (HIMS) Expands GLP 1 Offerings With Novo Nordisk Deal And Eucalyptus Buy

Hims & Hers Health (NYSE:HIMS) is expanding its GLP-1 weight-loss treatment offerings, adding new options to its telehealth platform. The…